
MEDIAN Group announces continued growth and a strong performance in 2024
- Double-digit growth in revenue to €2.3bn – continued efficiency improvements
- Providing high quality care for 309,000 patients and residents – an increase of 16,000 vs prior year
- 28,000 patients used MyMEDIAN@Home digital aftercare app in 2024
MEDIAN Group, a leading pan-European provider of mental health, specialist care and rehabilitation services, has announced strong financial results for 2024. The Group’s revenue has grown by 11% to €2.3bn, marked by a double-digit growth in EBITDA[1].
MEDIAN Group operates MEDIAN in Germany, Priory in the UK, and Hestia in Spain. Occupancy rates rose by 2% in 2024 compared to 2023, with the Group supporting over 16,000 additional patients and residents.
MEDIAN Group CEO, Philipp Schulte-Noelle, said: “2024 was a year of strong financial performance across the MEDIAN Group, thanks to elevated demand for our high quality services and our continued focus on operational excellence and efficiency. Investing in our infrastructure and new technology is a priority to ensure we continue to provide high value health and social care services efficiently.
“Our focus is on evidence-based care, data-driven insight and innovative technologies, coupled with an agile approach to driving growth. This means MEDIAN Group is ideally placed to meet rapidly growing societal challenges and to play a key role in setting the standards for the mental health and rehabilitation care of the future.”
The Group has made substantial investments in digital therapy to enhance support for patients both during treatment and after discharge from inpatient facilities. Recently the German Pension Fund adopted its proprietary app MyMEDIAN@Home as an approved treatment protocol – alongside the remote therapy delivered by its digital aftercare centre in Düsseldorf.
MEDIAN Group’s focus on harnessing the strengths and combined expertise of its three distinct organisations has positioned it at the forefront of emerging treatments and techniques. Last year saw the launch of the MEDIAN Group Lab, which has created a space for the Group to collaborate with tech organisations and start-ups to bring novel treatments into clinical practice quicker. One such development, PeakProfiling, forms part of a patient study in Germany and the UK, and uses voice biomarkers as an objective indicator of symptoms of mental ill health. The Group’s first International Medical Board also launched in 2024 as a forum for some of the most experienced MEDIAN Group clinicians and leaders from across Europe to work together on common challenges and explore opportunities.
MEDIAN Group CFO, Matthias Oehmicke, said: “Our strong revenue growth in 2024, combined with strong operational performance, has laid a solid foundation for 2025. Efficiency gains have led to improved cash flow generation enabling us to keep investing in our infrastructure across the Group.
“We continue to invest in sustainable services which contribute positively to the communities we serve, and will invest €25 million by 2026 in photovoltaic technology (solar panels) across ~140 facilities in Germany, the UK and Spain reducing CO2 and energy costs by ca €4 million.”
MEDIAN Group’s quality scores and regulatory ratings remain high and above the national average within their respective countries.
[1] adjusted for extraordinary effects